Valuation: Ardelyx, Inc.

Market Cap 877M 759M 717M 650M 1.22B 83.8B 1.23B 8.55B 3.29B 42.65B 3.29B 3.22B 135B P/E 2026 *
-19.6x
P/E 2027 * 15.2x
Enterprise Value 877M 759M 717M 650M 1.22B 83.8B 1.23B 8.55B 3.29B 42.65B 3.29B 3.22B 135B EV / Sales 2026 *
1.79x
EV / Sales 2027 * 1.41x
Free-Float
95.86%
Yield 2026 *
-
Yield 2027 * -
1 day-1.68%
1 week-6.88%
Current month-6.88%
1 month-9.97%
3 months-38.14%
6 months-39.10%
Current year-39.62%
1 week 3.51
Extreme 3.51
3.92
1 month 3.51
Extreme 3.51
4.09
Current year 3.51
Extreme 3.51
8.4
1 year 3.51
Extreme 3.51
8.4
3 years 3.16
Extreme 3.16
10.13
5 years 0.49
Extreme 0.4902
10.13
10 years 0.49
Extreme 0.4902
16.3
Manager TitleAgeSince
Chief Executive Officer 61 01/03/2009
Director of Finance/CFO 55 04/11/2025
Chief Tech/Sci/R&D Officer 50 01/04/2026
Director TitleAgeSince
Director/Board Member 61 01/03/2009
Chairman 60 01/03/2014
Director/Board Member 59 01/03/2014
Date Insider Type Main position Quantity % Market Cap. Importance
8/21/26 A Sell

Chief Financial Officer

-1,558 0.0006%
8/21/26 A Sell

Controller/Auditor

-3,982 0.0016%
8/21/26 A Sell

Head of Human Resources

-15,136 0.0061%
Change 5-day change 1-year change 3-year change Capi.($)
-1.68%-6.88%-46.75%-23.31% 892M
+5.04%+3.27%+50.62%+105.43% 66.93B
+1.64%-2.89%+34.67%+80.49% 61.97B
-3.18%-0.78%-14.14%+376.43% 28.26B
+4.55%-0.08%+34.70%+17.28% 24.59B
+2.20%-4.72%+2.19%-12.71% 24.3B
+1.15%-2.26%+17.56%-16.53% 19.41B
-7.03%-9.16%+161.91%+303.00% 16.77B
+3.44%-1.68%-5.00%+541.17% 14.18B
+4.96%+4.63%-2.75%+879.79% 14B
Average +1.11%-4.08%+23.30%+225.10% 27.13B
Weighted average by Cap. +1.97%-2.85%+32.99%+175.19%

Financials

2026 *2027 *
Net sales 489M 423M 399M 362M 679M 46.7B 685M 4.77B 1.83B 23.77B 1.84B 1.8B 75.44B 624M 540M 510M 462M 867M 59.61B 874M 6.08B 2.34B 30.34B 2.34B 2.29B 96.3B
Net income -44.5M -38.53M -36.36M -32.96M -61.84M -4.25B -62.34M -434M -167M -2.16B -167M -163M -6.87B 62.15M 53.81M 50.79M 46.04M 86.37M 5.94B 87.07M 606M 233M 3.02B 233M 228M 9.59B
Net Debt - -
Logo Ardelyx, Inc.
Ardelyx, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of innovative medicines that meet significant unmet medical needs. The Company markets two therapies from the active ingredient tenapanor, a sodium/hydrogen exchanger (NHE3) inhibitor. Tenapanor, branded as IBSRELA, is approved in the United States for the treatment of adults with irritable bowel syndrome with constipation (IBS-C). Tenapanor, branded as XPHOZAH, is approved in the United States to reduce serum phosphorus in adults with chronic kidney disease on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy. It is also developing a next-generation NHE3 inhibitor, RDX10531, which has demonstrated in preclinical models to have improved solubility and potency compared to tenapanor. RDX10531 has applications across multiple therapeutic areas.
Employees
489
Date Price Change Volume
14/09/26 $3.520 -1.68% 4,363,889
11/09/26 $3.580 -1.10% 5,690,263
10/09/26 $3.620 -4.74% 4,047,355
09/09/26 $3.800 +0.80% 4,473,755
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
3.580USD
Average target price
12.90USD
Spread / Average Target
+260.34%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ARDX Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!